Benilde Cosmi Selected Research

Venous Thromboembolism

4/2024	D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results.
1/2023	Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study.
12/2022	D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study.
11/2021	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis.
10/2021	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis.
1/2021	Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
11/2020	Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study.
1/2019	D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants.
4/2017	Diagnostic Accuracy of a New d-Dimer Assay (Sclavo Auto d-Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients.
11/2016	An update on the pharmaceutical management of thrombosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Benilde Cosmi Research Topics

Disease

39	Venous Thromboembolism 04/2024 - 01/2002
25	Venous Thrombosis (Deep-Vein Thrombosis) 03/2024 - 04/2004
20	Hemorrhage 04/2024 - 01/2005
19	Thrombosis (Thrombus) 04/2021 - 06/2002
11	Neoplasms (Cancer) 01/2023 - 01/2002
10	Thrombophilia 04/2021 - 05/2003
8	Pulmonary Embolism 12/2022 - 08/2003
6	Thrombocytopenia (Thrombopenia) 10/2023 - 10/2015
5	COVID-19 01/2022 - 01/2020
4	Atrial Fibrillation 03/2024 - 08/2009
3	Stroke (Strokes) 03/2024 - 11/2016
3	Hypertension (High Blood Pressure) 10/2020 - 06/2010
3	Acute Coronary Syndrome 11/2016 - 06/2009
3	Protein S Deficiency (Deficiency, Protein S) 09/2004 - 08/2003
2	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2021 - 05/2004
2	Thromboembolism 02/2014 - 10/2006
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2005 - 06/2002
2	Protein C Deficiency 09/2004 - 08/2003
1	Venous Insufficiency 01/2022
1	Ulcer 01/2022
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 04/2021
1	Acute Kidney Injury (Acute Renal Failure) 03/2021
1	Respiratory Insufficiency (Respiratory Failure) 03/2021
1	Uterine Hemorrhage (Uterine Bleeding) 01/2021
1	Convalescence 12/2020
1	Hypercholesterolemia 10/2020
1	Diabetes Mellitus 10/2020
1	Cytokine Release Syndrome 01/2020
1	Infections 01/2020
1	Heart Failure 01/2018
1	Myocarditis (Carditis) 01/2018
1	Intermittent Claudication 05/2014
1	Varicose Veins (Varicose Vein) 02/2014
1	Coumarin Resistance 08/2012
1	Disseminated Intravascular Coagulation 05/2012
1	Sepsis (Septicemia) 05/2012
1	Septic Shock (Toxic Shock Syndrome) 05/2012
1	Postthrombotic Syndrome 02/2012
1	Obesity 06/2010

Drug/Important Bio-Agent (IBA)

35	fibrin fragment D (D-dimer)IBA 04/2024 - 01/2002
25	AnticoagulantsIBA 03/2024 - 01/2002
11	Heparin (Liquaemin)FDA LinkGeneric 10/2023 - 05/2012
11	Vitamin K FDA Link 01/2021 - 10/2006
8	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022 - 02/2009
6	factor V LeidenIBA 01/2021 - 08/2003
5	RivaroxabanIBA 04/2021 - 10/2015
5	SuspensionsIBA 06/2010 - 05/2005
5	Fumigant 93 (D-D)IBA 01/2010 - 05/2005
4	apixabanIBA 04/2024 - 11/2016
4	Warfarin (Coumadin)FDA LinkGeneric 07/2021 - 07/2003
4	AntithrombinsIBA 10/2015 - 08/2003
3	Enoxaparin (Lovenox)FDA LinkGeneric 01/2020 - 10/2015
3	Protein CIBA 05/2012 - 04/2004
2	Factor Xa InhibitorsIBA 04/2021 - 01/2018
2	edoxabanIBA 04/2021 - 11/2016
2	Prothrombin (Factor II)IBA 01/2021 - 03/2013
2	Factor VIII (Coagulation Factor VIII)IBA 01/2008 - 11/2004
2	Oral ContraceptivesIBA 11/2004 - 04/2004
2	Antiphospholipid AntibodiesIBA 09/2004 - 08/2003
1	insulin receptor-related receptor (IRR)IBA 04/2024
1	cupric sulfide (CuS)IBA 03/2024
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Hemoglobins (Hemoglobin)IBA 10/2021
1	CreatinineIBA 10/2021
1	argatroban (MPQA)FDA Link 03/2021
1	Factor V (Coagulation Factor V)IBA 01/2021
1	Antiviral Agents (Antivirals)IBA 12/2020
1	betrixabanIBA 12/2020
1	Fondaparinux (Arixtra)FDA Link 10/2020
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2020
1	PRT064445IBA 04/2018
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2018
1	Factor XI (Plasma Thromboplastin Antecedent)IBA 11/2016
1	idarucizumabIBA 11/2016
1	Dabigatran FDA Link 11/2016
1	Factor XII (Hageman Factor)IBA 11/2016
1	IodoacetamideIBA 05/2016
1	AmmoniaIBA 05/2016
1	AntibodiesIBA 12/2015
1	Platelet Factor 4IBA 12/2015
1	Immunoglobulin G (IgG)IBA 12/2015
1	Thrombin FDA Link 10/2015
1	Pain-FreeIBA 05/2014
1	parnaparinIBA 02/2014
1	FluxumIBA 02/2014
1	Carboxypeptidase B2 (Thrombin Activatable Fibrinolysis Inhibitor)IBA 08/2012
1	Dacarbazine (DIC)FDA LinkGeneric 05/2012
1	Hormones (Hormone)IBA 02/2011
1	snake venom protein C activatorIBA 08/2010

Therapy/Procedure

21	Therapeutics 01/2023 - 01/2002
2	Compression Stockings 01/2022 - 02/2012
2	Secondary Prevention 04/2021 - 11/2016
1	Thrombectomy 01/2022
1	Compression Bandages 01/2022
1	Hormonal Contraception 01/2021
1	Contraindications 12/2020
1	Carotid Endarterectomy 10/2020
1	Knee Replacement Arthroplasty (Total Knee Replacement) 11/2016
1	Surgical Amputation (Amputations) 05/2014